Welcome to our dedicated page for Innovate SEC filings (Ticker: VATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The INNOVATE Corp. (NYSE: VATE) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Form 8-K current reports and other key documents. These filings provide detail on INNOVATE’s portfolio across its Infrastructure, Life Sciences and Spectrum segments and on its capital structure.
Form 8-K current reports for INNOVATE frequently announce quarterly financial results, segment performance and significant events at portfolio companies. Examples include earnings releases for the second and third quarters, updates on DBM Global Inc. cash dividends, and press releases about MediBeacon’s regulatory approvals in the United States and China and R2 Technologies’ growth in Glacial Skin CryoAesthetics platforms.
INNOVATE also uses Form 8-K to disclose financing and refinancing transactions. Recent filings describe exchanges of senior secured notes for new notes with extended maturities, amendments to convertible notes, extensions of the company’s revolving credit agreement, changes to a subordinated secured promissory note with Continental General Insurance Company and extensions of Spectrum and R2 Technologies notes. These documents outline the terms of the new instruments, maturity dates, interest rates and related conditions.
Through this page, users can track how INNOVATE reports revenue by segment, net income or loss by segment and Adjusted EBITDA in its earnings-related filings, as well as how it documents material events such as regulatory approvals and strategic processes linked to debt covenants. Stock Titan’s interface surfaces new filings as they appear on EDGAR and offers AI-powered summaries to help interpret lengthy disclosures, from note exchange terms to segment-level commentary.
Investors researching VATE can review Forms 8-K and related exhibits here to understand INNOVATE’s reporting practices, segment updates, debt profile and the regulatory record of its portfolio companies.
INNOVATE Corp. Chief Financial Officer Michael J. Sena reported routine tax-related share dispositions. Over three days, a total of 7,911 shares of common stock were withheld by the company to cover taxes tied to vesting of restricted stock, at prices between $4.22 and $4.35 per share. After these non-market tax-withholding transactions, he directly holds 115,982 common shares.
INNOVATE Corp. reported that MediBeacon, in which it holds a 44.7% equity interest, had a peer-reviewed article on its transdermal GFR (tGFR) measurement recognized as one of five 2025 Editors’ Choice articles by the Journal of the American Society of Nephrology.
The featured work describes MediBeacon’s TGFR System, which uses the Lumitrace (relmapirazin) fluorescent tracer and a wearable sensor to measure kidney function through the skin at the point of care. The article was featured on the journal’s August 2025 cover.
The TGFR System is approved for human use, and commercialization through centers of excellence in select academic medical centers began in January 2026, initially focusing on heart failure monitoring, transplant evaluation and oncology drug dosing.
INNOVATE Corp. filed a current report to note that one of its portfolio companies, referred to as Global, plans to pay a cash dividend. The company disclosed this by issuing a press release titled “INNOVATE’s Portfolio Company Global to Pay Cash Dividend,” which is included as an exhibit.
The press release is attached as Exhibit 99.1 and is furnished rather than filed, meaning it is not automatically incorporated into other securities law filings. The report also includes the cover page interactive data file as Exhibit 104.
INNOVATE Corp. reported that on December 16, 2025 it issued a press release titled “MediBeacon® Next Generation TGFRTM System Receives FDA Approval,” announcing that this MediBeacon system has received FDA approval. This highlights a notable regulatory milestone for that product.
The company is sharing the news with investors through the press release, which is attached as Exhibit 99.1 and is not deemed filed for purposes of Section 18 of the Exchange Act or automatically incorporated into Securities Act filings. INNOVATE’s common stock, par value $0.001 per share, is listed on the New York Stock Exchange under the symbol VATE.
Whitefort Capital Management, with David Salanic and Joseph Kaplan, filed Amendment No. 1 to Schedule 13G reporting 7.8% beneficial ownership of INNOVATE Corp. (VATE), totaling 1,059,897 shares as of September 30, 2025.
The position comprises 743,000 shares plus $13,409,255 principal amount of the issuer’s 9.5% convertible senior notes due 2027, currently convertible into 316,897 shares. The percentage is based on 13,336,149 shares outstanding as of August 1, 2025. The reporting persons disclose shared voting and dispositive power over the reported shares and certify the securities were not acquired to change or influence control.
INNOVATE Corp. (VATE) filed its Q3 2025 10‑Q, reporting stronger topline but continued losses and a going concern warning. Revenue rose to
Net loss attributable to common and participating preferred was
The company disclosed substantial doubt about its ability to continue as a going concern, citing upcoming maturities of Corporate, Spectrum, and R2 Technologies debt and cross‑default provisions under its
INNOVATE Corp. (VATE) furnished its Q3 2025 results update. The company announced results for the three and nine months ended September 30, 2025 via a press release and investor presentation, furnished under Items 2.02 and 7.01.
Exhibits include the Earnings Release (99.1) and Third Quarter 2025 Conference Call Investor Presentation (99.2). A conference call and simultaneous webcast are scheduled for November 12, 2025 at 4:30 p.m. ET on the Investor Relations section of the company’s website.
INNOVATE Corp. filed an 8-K announcing a press release titled “MediBeacon receives regulatory approval to sell the Transdermal GFR System in China.” The company states the press release is attached as Exhibit 99.1.
Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and it is not incorporated by reference into Securities Act filings unless specifically referenced.
INNOVATE Corp. filed an 8-K announcing that its portfolio company, DBM Global, plans to pay a cash dividend. The company issued a press release titled “INNOVATE’s Portfolio Company DBM Global to Pay Cash Dividend” on October 16, 2025, which is attached as Exhibit 99.1.
The press release is furnished and not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference under the Securities Act unless specifically referenced in a future filing. INNOVATE’s common stock trades on the NYSE under the symbol VATE.
INNOVATE Corp. (VATE) Form 4/A shows amended insider reporting by Avram A. Glazer, related trust and affiliates reflecting conversions of company convertible notes. The amendment adds Lancer Capital LLC as an additional reporting owner and clarifies indirect ownership through the Avram Glazer Irrevocable Exempt Trust and familial relationships.
The filing shows convertible instruments with a $42.3143 conversion price. For the 9.5% Convertible Senior Notes due 2027, the filing reports beneficial ownership of 2,195,000 common shares following the reported transaction, held indirectly through Lancer Capital. Signatures are dated 09/18/2025.